Effective Dec. 8, 2020, Wisconsin Diagnostic Laboratories (WDL) is implementing a new Urinalysis System. With this implementation, reference ranges and reportable results will change for select tests included in routine urinalysis testing.
Effective Aug. 17, 2020,Chromogranin A testing will be performed using an alternate method. Since Chromogranin A tests are not harmonized, quantitative results are not directly comparable between the current and new test.
Effective July 8, 2020, Wisconsin Diagnostic Laboratories will begin offering a new test for fecal calprotectin.
Effective Jan. 29, 2020, WDL will begin in-house testing for the anti-epileptic drug CLOBAZAM (ONFI) and its active metabolite DESMETHYLCLOBAZAM. Bringing this test in-house will significantly improve turnaround time.
Effective Jan. 15, 2020, WDL will offer a new test for assessment of vitamin B12 status, VITAMIN B12 REFLEX TO METHYLMALONIC ACID. This new reflex test will be the preferred test for assessment of vitamin B12 status, replacing parallel testing of vitamin B12 and methylmalonic acid. This change aligns with current best-practices, which recommend methylmalonic acid testing only as follow up in cases of borderline deficient or low vitamin B12.